期刊文献+

重组人B淋巴细胞刺激因子受体-抗体融合蛋白的肽图分析 被引量:2

Peptide mapping analysis of recombinant human B lymphocyte stimulator receptor:IgG Fc fusion protein
原文传递
导出
摘要 目的:建立重组人B淋巴细胞刺激因子受体-抗体融合蛋白(TACI-Fc)的肽图分析方法。方法:将TACI-Fc蛋白用胰蛋白酶酶解、用尿素将蛋白分子变性、用二硫苏糖醇打断二硫键、用碘乙酰胺封闭巯基、用胰蛋白酶再次酶解等方法处理后,采用高效液相色谱分析,色谱柱为Vydac C18(250 mm×4.6 mm,5μm),流动相A液为含0.1%三氟乙酸的水溶液,流动相B液为含0.1%三氟乙酸的乙腈溶液,梯度洗脱,流速为1.0 mL.min-1,检测波长为214 nm。结果:TACI-Fc蛋白被有效酶解,酶解后的各个片段能够很好的分离。结论:本法准确性高,重复性好,是重组人B淋巴细胞刺激因子受体-抗体融合蛋白结构确认的有效方法。 Objective:To establish a peptide mapping analysis method in recombinant human B lymphocyte stimulator receptor:IgG Fc fusion protein.Method:The TACI-Fc protein was digested with trypsin and then was denatured by urea.Next,the disulfide bonds were interrupted by dithiothreitol and the thiol groups were closed with iodoacetamide.Finally,the treated TACI-Fc protein was digested with trypsin again and assayed by HPLC.Vydac C18(250 mm×4.6 mm,5 μm) was used as analysis column,0.1% trifluoroacetic acid in water and 0.1% trifluoroacetic acid in acetonitrile were used as mobile phase A and mobile phase B,respectively.The gradient elution process was performed.The detection wavelength was 214 nm and flow rate was 1.0 mL·min-1.Results:The fragments of TACI-Fc were well digested and separated.Conclusion:This method is accurate,stable,and reliable for testing of human B lymphocyte stimulator receptor:IgG Fc fusion protein peptide mapping.
出处 《药物分析杂志》 CAS CSCD 北大核心 2011年第6期1185-1187,共3页 Chinese Journal of Pharmaceutical Analysis
关键词 重组 淋巴细胞 刺激因子 受体 抗体 融合蛋白 肽图 recombinant lymphocyte stimulator receptor antibody fusion protein peptide mapping
  • 相关文献

参考文献4

  • 1Nestorov Ⅰ,Munafo A,Papasouliotis O,et al.Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis.J Chin Pharmacol,2008,48(4):406. 被引量:1
  • 2Bracewell C,Isaacs JD,Emery P,et al.Atacicept,a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis.,2009,9(7):909. 被引量:1
  • 3Dall'Era M,Chakravarty E,Wallace D,et al.Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus:results of a multicenter,phase Ib,double-blind,placebo-controlled,dose-escalating trial.Arthritis Rheum,2007,56(12):4142. 被引量:1
  • 4ChP(中国药典).2010.Vol Ⅲ(三部):95,101,119,162. 被引量:4

共引文献3

同被引文献18

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部